10-Q: Vaso Corp. Q2 Loss Widens on Higher Costs

Vaso Corporation reported a significant widening of its net loss and operating loss for the second quarter and first half of 2025, primarily due to increased selling, general, and administrative expenses.

Summary

• Total revenues for the three months ended June 30, 2025, decreased by 1% year-over-year to $19.96 million, while for the six months ended June 30, 2025, they increased by 1% to $39.42 million.
• The IT segment's revenue increased by 1% in both the three-month ($10.68 million) and six-month ($21.00 million) periods, with monthly recurring revenue accounting for 89% and 90% of segment revenue, respectively.
• The professional sales service segment's revenue decreased by 4% in the three-month period to $8.74 million but increased by 1% in the six-month period to $17.45 million.
• Net loss for the three months ended June 30, 2025, was $197,000, a significant decrease from net income of $1.16 million in the prior year period.
• Net loss for the six months ended June 30, 2025, increased to $1.27 million from $18,000 in the prior year period.
• Operating loss for the three months ended June 30, 2025, was $421,000, compared to operating income of $996,000 in the prior year period.
• Operating loss for the six months ended June 30, 2025, increased to $1.64 million from $473,000 in the prior year period.
• Adjusted EBITDA for the three months ended June 30, 2025, was negative $253,000, down from positive $1.20 million in the prior year period.
• Adjusted EBITDA for the six months ended June 30, 2025, was negative $1.37 million, a substantial decrease from negative $65,000 in the prior year period.
• Selling, general, and administrative (SG&A) costs increased by 11% in the three-month period to $12.05 million and by 7% in the six-month period to $24.45 million.
• Cash and cash equivalents increased to $32.56 million at June 30, 2025, from $26.27 million at December 31, 2024.
• Net cash provided by operating activities significantly increased to $6.23 million for the six months ended June 30, 2025, compared to $1.72 million in the prior year period.
• Deferred revenue, representing unfulfilled performance obligations, increased to $38.11 million at June 30, 2025, from $34.89 million at December 31, 2024, with an aggregate of approximately $108 million expected to be recognized in future periods.

Sentiment

Score: 3

Explanation: The significant widening of net and operating losses, coupled with negative Adjusted EBITDA for both the quarter and year-to-date, indicates a deteriorating financial performance despite some revenue stability and improved cash flow from operations. Increased SG&A costs are a concern, outweighing the positives of increased cash and deferred revenue.

Positives

• Cash and cash equivalents increased to $32.56 million at June 30, 2025, from $26.27 million at December 31, 2024.
• Net cash provided by operating activities significantly improved to $6.23 million for the six months ended June 30, 2025, compared to $1.72 million in the prior year period.
• The IT segment demonstrated revenue growth of 1% in both the three-month and six-month periods, with a high proportion of monthly recurring revenue (89% and 90% respectively).
• Deferred revenue, representing future recognized income from existing contracts, increased to $38.11 million, indicating strong order bookings.
• The equipment segment's operating loss improved by $128,000 in Q2 2025 and by $175,000 in H1 2025, primarily due to lower SG&A and R&D costs in China operations.

Negatives

• Net loss for the three months ended June 30, 2025, was $197,000, a significant deterioration from net income of $1.16 million in Q2 2024.
• Net loss for the six months ended June 30, 2025, increased substantially to $1.27 million from $18,000 in H1 2024.
• Operating loss for Q2 2025 was $421,000, a sharp decline from operating income of $996,000 in Q2 2024.
• Operating loss for H1 2025 widened to $1.64 million from $473,000 in H1 2024.
• Adjusted EBITDA turned negative in Q2 2025 at $253,000 and significantly worsened in H1 2025 to $1.37 million.
• Selling, general, and administrative (SG&A) costs increased by 11% in Q2 and 7% in H1, contributing to the widened losses.
• Total revenues for Q2 2025 decreased by 1% year-over-year, primarily due to a 4% decrease in the professional sales service segment.
• Gross profit decreased by 3% in Q2 2025, with the IT segment experiencing a 6% decrease in gross profit due to product mix changes and higher costs.

Risks

• The Company was not in compliance with financial covenants of its $3.0 million revolving credit agreement as of June 30, 2025, though a waiver was subsequently received.
• Dependence on GE Healthcare, which accounted for 44% of total revenue and 54% of accounts and other receivables at June 30, 2025.
• Exposure to general business and economic conditions, including potential downturns or disruptions in the U.S. economy.
• Impact of U.S. tariff policies on business operations and financial results.
• The effect of dramatic changes taking place in the IT and healthcare industries.
• Risk related to the continuation of the GEHC agreement, which is subject to early termination conditions.
• Impact of competitive technology and products and their pricing on market share and profitability.
• Changes in medical insurance reimbursement policies could affect demand for products and services.
• Potential for unexpected manufacturing or supplier problems impacting operations.
• Unforeseen difficulties and delays in product development programs.
• Actions of regulatory authorities and third-party payers in the United States and overseas.
• The recently signed H.R.1, the One Big Beautiful Bill Act (OBBBA), could have an impact on income tax expense in future periods due to changes in tax provisions.

Future Outlook

The Company intends to continue seeking opportunities to increase stockholder value through internal growth, new partnerships, and strategic investments, with a focus on medical and IT service companies. The full impact of the recently signed One Big Beautiful Bill Act (OBBBA) on future income tax expense is currently being analyzed.

Management Comments

• We intend to continue to seek opportunities to increase stockholder value, including through internal growth, new partnerships and strategic investments with a concentration on medical and IT service companies.

Industry Context

The filing acknowledges the dramatic changes taking place in the IT and healthcare industries, which are core to Vaso Corporation's business segments. It also highlights the importance of medical insurance reimbursement policies and the impact of competitive technology and products, suggesting a dynamic and challenging market environment. The company's significant reliance on GE Healthcare for its professional sales service segment indicates a concentrated industry relationship.

Legal Proceedings

• The Company is currently, and has been in the past, a party to various legal proceedings, primarily employee-related matters, incident to its business. The Company believes that the outcome of all pending legal proceedings in the aggregate is unlikely to have a material adverse effect on the business or consolidated financial condition.

Related Party Transactions

• The Company holds a 49% minority interest in EECP Global Corporation and accounts for it using the equity method.
• The Company and EECP Global's majority shareholder converted $220,000 in receivables due from EECP Global into capital contributions as of June 30, 2025.
• The Company's share of EECP Global's loss was approximately $43,000 for Q2 2025 and $111,000 for H1 2025.
• A net receivable from related parties of approximately $1.09 million was recorded at June 30, 2025, for amounts due from EECP Global.

Stakeholder Impact

• Shareholders are negatively impacted by the significant widening of net and operating losses, and negative Adjusted EBITDA, which could pressure share price.
• Employees in the professional sales service segment saw additional sales headcount and compensation costs, while China operations in the equipment segment experienced lower personnel costs.
• Customers of the IT segment benefit from increased network service revenues and a high proportion of monthly recurring revenue.
• Customers of the professional sales service segment experienced lower deliveries of diagnostic imaging equipment but increased deliveries of ultrasound products from GEHC.
• Creditors, particularly the lending institution for the revolving credit agreement, faced non-compliance with financial covenants, though a waiver was obtained, indicating ongoing monitoring.

Next Steps

• Evaluate the impact of adopting ASU 2024-03, Income Statement Reporting Comprehensive Income Expense Disaggregation Disclosures, on consolidated financial statements.
• Analyze the full impact of the One Big Beautiful Bill Act (OBBBA) on future income tax expense.
• Seek opportunities to increase stockholder value through internal growth, new partnerships, and strategic investments, particularly in medical and IT service companies.

Key Dates

Recommendation

The substantial increase in net loss and operating loss, along with negative Adjusted EBITDA for both the quarter and year-to-date, signals a concerning deterioration in profitability. While cash flow from operations improved and deferred revenue increased, the core business segments are struggling with rising costs, particularly SG&A, and mixed revenue performance. The non-compliance with credit covenants, even if waived, adds a layer of financial risk. These factors suggest a negative outlook for investors, warranting a 'sell' recommendation.

Keywords

Vaso Corporation, VASO, 10-Q, Quarterly Report, Financial Results, Healthcare IT, Medical Devices, Professional Sales Services, GE Healthcare, Net Loss, Operating Loss, Adjusted EBITDA, Deferred Revenue, Cash Flow, SEC Filing